Yang Zou

Dr. Yang Zou

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LYLinhan Yang
Linhan Yang
YZYang Zou
Yang Zou
JFJihua Fan
Jihua Fan
PYPu Yin
Pu Yin
HQHan Qin
Han Qin
SLSunny C. Li
Sunny C. Li
Background: Alzheimer’s disease (AD) is the most common dementia, characterized by significant cognitive impairments and neural network dysfunction. Currently, multiple therapeutic strategies are being developed to design effective anti-AD drugs. Among them, Withaferin A (WA), a natural steroidal lactone extracted from Withania somnifera leaves, has been shown to reduce amyloid-β (Aβ) peptide levels in vitro. However, its potential to improve cognitive function in AD remains unclear. Methods: In this study, 5xFAD mice were administered WA (2 mg/kg intraperitoneally every 2 days) for 14 days, and its neuroprotective effects were evaluated through behavioral tests, wide-field imaging, immunohistochemistry, and ELISA. Results: WA significantly improved short-term memory, as evidenced by enhanced performance in the Novel Object Recognition Test (NORT) (p < 0.001, n = 10), Novel Location Recognition Test (NLRT) (p < 0.01, n = 14), and Three-Chamber Social Test (TCST) (p < 0.001, n = 8). WA also ameliorated long-term memory deficits in the Morris Water Maze Test (MWMT) (p < 0.05, n = 7). Furthermore, cortical wide-field Ca2+ imaging revealed that WA treatment rescued slow-wave impairments by enhancing long-range coherence (0.8363 ± 0.0185, p < 0.01, n = 8) and reducing the frequency of slow-wave activity (0.6578 ± 0.0512 Hz, p < 0.01, n = 8). Additionally, WA treatment significantly reduced Aβ plaque deposition in both cortical and hippocampal regions. Conclusions: These findings suggest that WA may be a promising therapeutic agent for AD, exerting neuroprotective effects.

28 May 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YZYang Zou
Yang Zou
YLYanni Lin
Yanni Lin
CZChenglong Zhang
Chenglong Zhang
YLYang Li
Yang Li
XCXiaoping Chen
Xiaoping Chen
PLPeng Liang
Peng Liang
Introduction: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques and pervasive cognitive decline. Bavachinin, a natural flavonoid derived from the traditional medicinal herb Psoralea corylifolia, has previously been demonstrated to inhibit Aβ aggregation in vitro . However, its potential to alleviate cognitive impairment, restore large-scale brain network dysfunctions, and mitigate AD-related pathology in vivo remains elusive. Methods: In this study, we systematically evaluated the therapeutic efficacy of bavachinin on AD-associated pathology, cortical slow-wave activity (SWA), and behavioral phenotypes in 5xFAD transgenic mice. We utilized behavioral assessments to evaluate learning and memory, mesoscopic wide-field calcium imaging to assess cortical network dynamics, and histological analyses to measure cerebral Aβ deposition. Furthermore, pharmacological inhibition was employed to investigate the mechanistic role of mitochondrial oxidative phosphorylation (OXPHOS). Results: Behavioral assessments revealed that bavachinin administration significantly rescued deficits in learning and memory. Mesoscopic wide-field calcium imaging further demonstrated that bavachinin substantially enhanced the synchrony of cortical SWA while reducing its frequency in 5xFAD mice, indicating a restoration of network-level dynamics. Histological analyses confirmed a marked reduction in cerebral Aβ deposition, which occurred independent of Aβ production pathways. Mechanistically, bavachinin bolstered microglial Aβ phagocytosis and chemotactic migration by promoting mitochondrial OXPHOS, thereby revitalizing cellular energy metabolism. Notably, pharmacological inhibition of OXPHOS partially abrogated the therapeutic benefits of bavachinin, suggesting that the augmentation of mitochondrial function is a requisite for its anti-AD effects. Discussion: In summary, bavachinin alleviates cognitive impairment and neuropathology in AD model mice by driving microglial metabolic reprogramming and facilitating Aβ clearance. These findings highlight its robust potential as a therapeutic candidate for AD.

28 September 2026 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
YZYang Zou
Yang Zou
JYJun Yang
Jun Yang
YLYang Li
Yang Li
GWGuodong Wang
Guodong Wang
WLWen Lu
Wen Lu
TZTao Zhuo
Tao Zhuo
Background: Although depression is a potent risk factor for Alzheimer's disease (AD), the underlying causal mechanisms remain unclear. This study investigated the molecular and circuit‐level mechanisms linking chronic stress to accelerated AD pathogenesis and evaluated the therapeutic potential of precise mTORC1 targeting. Methods: A chronic restraint stress (CRS) paradigm was established in 5xFAD mice. Multi‐scale neurofunctional and histopathological alterations were deconstructed using behavioral profiling, wide‐field and two‐photon calcium imaging, immunofluorescence, and bulk RNA‐sequencing. Pharmacological intervention was conducted using the specific mTORC1 inhibitor EN6. Results: CRS severely impaired cortical slow‐wave oscillations and induced aberrant prefrontal single‐neuron hyperactivity, exacerbating cognitive decline. These network deficits were accompanied by accelerated AD hallmarks, including elevated Aβ deposition, dystrophic neurite aggravation, and reactive gliosis. Mechanistically, transcriptomic profiling and biochemical validation revealed that chronic stress suppresses autophagic pathways via selective hyperactivation of mTORC1 signaling rather than the AMPK pathway. Time‐course analysis showed that mTORC1 activation and autophagy‐related abnormalities preceded overt Aβ accumulation, while pharmacological mTOR activation with MHY1485 further aggravated autophagic impairment and increased Aβ42 levels. Crucially, targeted mTORC1 inhibition with EN6 ameliorated autophagy‐related abnormalities and was associated with reduced BACE1 abundance and CTFβ generation, together with a diminished global Aβ burden. This microenvironmental stabilization attenuated neuroinflammation, realigned neural networks, and rescued both cognitive and emotional deficits. Conclusion: Chronic stress‐induced mTORC1 hyperactivation is associated with autophagic impairment, contributing to macro‐circuit desynchronization and accelerated amyloid accumulation. Targeting the mTORC1–autophagy axis represents a potential therapeutic approach to mitigate neural network breakdown and neuropathology in stress‐related neurodegenerative conditions.

1 September 2026 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
ZZZiyi Zhang
Ziyi Zhang
LALin Ai
Lin Ai
XZXi Zheng
Xi Zheng
JZJun Zhang
Jun Zhang
ZLZujian Li
Zujian Li
HQHan Qin
Han Qin
BACKGROUND: Precise control of propofol anesthesia depth is critical for perioperative safety; however, the dynamic reorganization of large-scale cortical functional networks throughout propofol anesthesia and recovery remains incompletely understood. This study employs wide-field imaging to record neuronal activity and functional connectivity across the entire cortex to investigate these cortical network dynamics during propofol anesthesia and emergence. METHODS: By synchronously recording behavioral videos and electroencephalogram-electromyogram signals, we characterized the anesthesia depth in head-fixed mice. We performed retro-orbital sinus injections of AAV2/PHP.eB-hSyn-jGCaMP8s in 8-week-old C57BL/6J mice and recorded Ca 2+ signals from the dorsal cortex under a wide-field microscope. Through functional connectivity analyses in different anesthesia stages, we elucidated the dynamic changes in functional connectivity between different cortical regions during propofol anesthesia. RESULTS: Wide-field Ca 2 + imaging revealed a progressive, global suppression of cortical activity as propofol anesthesia deepened, followed by partial recovery upon emergence. During the burst-suppression stage, brief high-amplitude slow waves transiently synchronized activity across all recorded cortical regions, resulting in maximal functional connectivity. In contrast, the persistent desynchronization following emergence exhibited region-specific patterns, with a greater reduction in intra-area coherence observed in motor and somatosensory cortices (Wake_pre vs Recovery: secondary motor cortex (MOs)-primary motor cortex (MOp), somatosensory, barrel field cortex (SSb)-somatosensory, upper limb cortex (SSu), SSb-somatosensory, lower limb cortex (SSl), SSu-SSl; P < 0.05) compared with visual and retrosplenial cortices. After emergence, the inter-regional correlation coefficient declined and remained below pre-anesthesia baseline for at least 1.5 hours, despite recovery of local cortical Ca 2 + activity (Wake_pre vs Recovery (mean ± SEM): 0.82 ± 0.02 vs 0.67 ± 0.03 for motor cortex (MO)-somatosensory cortex (SS), 0.61 ± 0.06 vs 0.46 ± 0.06 for MO-visual cortex (VIS), 0.69 ± 0.03 vs 0.54 ± 0.06 for MO-retrosplenial cortex (RSP), 0.72 ± 0.03 vs 0.50 ± 0.10 for SS-RSP; P < 0.05). CONCLUSIONS: These findings demonstrate a dissociation between recovery of local cortical activity and restoration of large-scale network coordination during emergence from propofol anesthesia. The persistence of impaired inter-regional synchrony after behavioral recovery suggests that normalization of cortical network integration lags behind the return of consciousness. This multimodal framework provides network-level insights into anesthesia-induced brain state transitions and has implications for improving perioperative monitoring and management.